Saturday 17 October 2026
Export BTAIQ’s income statement to Excel — free account
BioXcel Therapeutics, Inc.
BTAIQ Healthcare Drug Manufacturers Specialty & Generic
BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024. In the quarter to June 2026, revenue grew 51.7%, EPS grew 80.0%, free cash flow grew 51.5% and total debt fell 3.90%, each against the same quarter a year earlier.
0.03
0.00
0.00%
Follow BTAIQ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 2 | 2 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 0.00 | 61.86 | 6.69 | 30.42 |
Altman Z-Score |
— | — | — | — | — | — | (1.57) | (17.76) | (28.93) | (26.30) |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (5.69) | (38.25) | (65.22) | (61.88) |
P/Operating CF |
— | — | — | — | — | — | (15.56) | (3.18) | (1.02) | (1.37) |
Beneish M-Score |
— | — | — | — | — | — | — | 2.30 | (0.08) | (0.61) |
P/B ratio |
— | — | — | — | — | — | 7.83 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | — | 7.83 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | — | 0.00 | 87.74 | 38.90 | 156.34 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (3.70) | (0.78) | (1.22) | (1.74) |
EV/FCF |
— | — | — | — | — | — | (3.70) | (0.78) | (1.22) | (1.74) |
Quick Ratio |
0.00 | 0.38 | 9.16 | 3.83 | 18.00 | 13.98 | 5.90 | 2.39 | 1.35 | 0.54 |
Current Ratio |
0.01 | 0.38 | 9.26 | 4.03 | 18.33 | 14.21 | 6.17 | 2.65 | 1.68 | 0.83 |
Net Debt/EBITDA |
0.00 | 0.11 | 2.13 | 0.93 | 2.58 | 2.17 | 0.63 | (0.21) | (1.09) | (1.61) |
Debt/Assets |
0.00% | 27.38% | 0.00% | 3.28% | 0.74% | 0.58% | 45.40% | 136.49% | 267.38% | 244.00% |
Debt/Equity |
0.00 | (0.38) | 0.00 | 0.04 | 0.01 | 0.01 | 1.22 | (1.78) | (1.10) | (1.15) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.02 |
Operating CF/Net income |
0.61 | 0.48 | 0.70 | 0.82 | 0.81 | 0.77 | 0.82 | 0.87 | 1.21 | 0.82 |
Capex/Depreciation |
0.00 | 0.00 | (20.00) | (5.58) | (1.68) | (1.50) | (0.43) | (0.06) | 0.00 | 0.00 |
Interest Coverage |
— | — | (28.85) | (1,680.05) | (3,048.04) | (2,673.37) | (19.44) | (12.90) | (4.44) | (2.97) |
| 324.66% | 695.10% | (101.67%) | (100.23%) | (70.35%) | (49.93%) | (111.08%) | (1,766.94%) | 79.67% | 74.14% | |
| (311.31%) | (666.52%) | (85.83%) | (82.48%) | (64.11%) | (46.55%) | (74.45%) | (128.10%) | (106.39%) | (167.91%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
654.32% | 314.55% | (49.62%) | (123.57%) | (39.79%) | (48.29%) | (96.90%) | (392.14%) | (381.17%) | 770.98% |
Average Days of Receivables |
— | — | 0.00 | — | — | — | 241.39 | 18.78 | 21.10 | 132.47 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24,330.40% | 6,110.58% | 1,343.12% | 4,711.99% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18,336.27% | 6,044.42% | 1,522.15% | 3,192.21% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4,623.20% | 1,348.84% | 271.67% | 431.00% |
Graham Net Nets |
— | — | — | — | — | — | 0.12 | (0.68) | (6.20) | (4.90) |
Graham Number |
— | — | — | — | — | — | 0.00 | 262.11 | 146.49 | 34.36 |
Earnings Yield |
— | — | — | — | — | — | (27.54%) | (209.90%) | (434.28%) | (419.38%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (22.54%) | (181.60%) | (475.27%) | (295.07%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.76 | 0.89 | 0.05 |
Operating CF per Share |
(2.18) | (3.63) | (14.83) | (26.62) | (48.96) | (49.84) | (77.30) | (85.12) | (28.41) | (4.72) |
Capex per Share |
(0.01) | 0.00 | (0.37) | (0.85) | (0.23) | (0.27) | (0.08) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.19) | (3.63) | (15.21) | (27.47) | (49.19) | (50.11) | (77.38) | (85.13) | (28.41) | (4.72) |
Cash per Share |
0.00 | 1.47 | 46.73 | 31.85 | 157.26 | 141.34 | 110.64 | 35.82 | 11.78 | 2.36 |
Shareholders Equity per Share |
(0.55) | (1.62) | 42.70 | 26.42 | 152.52 | 134.48 | 43.85 | (31.03) | (36.73) | (7.82) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.55) | (1.62) | 42.70 | 26.42 | 152.52 | 134.48 | 43.85 | (31.03) | (36.73) | (7.82) |
Free Cash Flow |
(1.30) | (2.20) | (13.85) | (27.97) | (66.67) | (82.60) | (135.48) | (155.03) | (72.03) | (57.61) |
Working Capital |
(0.33) | (1.45) | 38.51 | 25.64 | 205.22 | 220.15 | 169.97 | 44.88 | 15.16 | (9.24) |
Capital Expenditures |
0.00 | — | (0.34) | (0.87) | (0.32) | (0.44) | (0.14) | (0.02) | — | — |
Net Current Asset Value |
(0.33) | (1.45) | 38.51 | 24.61 | 203.83 | 219.04 | 73.79 | (58.07) | (94.04) | (95.69) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.37 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.25 | 0.05 | 0.15 | 0.15 | 0.23 | 0.30 | 0.41 | 0.65 | 1.71 |
Cash ROIC |
400.62% | (795.65%) | (17.00%) | (46.22%) | (15.82%) | (18.11%) | (37.22%) | (141.82%) | (183.46%) | (134.34%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 2.07 | 8.65 | 22.44 | 3.53 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.02 | 0.05 | 0.04 | 0.07 | 0.00 | 0.11 | 0.14 | 0.01 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 1.61 | 0.23 |
Average Days of Payables |
0.00 | 162,060.00 | 34,438.82 | 11,588.75 | 7,725.19 | 5,749.06 | 186,661.00 | 3,955.33 | 2,723.45 | 32,718.69 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36,226.25 | 576.76 | 115.65 | 1,606.89 |
Average Receivables |
— | — | — | — | — | — | 0.18 | 0.16 | 0.10 | 0.18 |
Average Payables |
0.36 | 0.36 | 1.02 | 3.28 | 4.47 | 4.33 | 7.45 | 11.94 | 14.82 | 15.35 |
Average Inventory |
— | — | — | — | — | — | — | 1.99 | 1.34 | 0.70 |
Average Assets |
0.68 | 0.68 | 22.45 | 39.97 | 128.16 | 229.69 | 222.65 | 139.78 | 56.02 | 41.63 |
Average Common Equity |
(0.65) | (0.65) | 18.95 | 32.89 | 116.80 | 214.18 | 149.22 | 10.13 | (74.80) | (94.28) |
Columns are period end dates